Lumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1. Phase 4.

Moiramide B is a potent acetyl coenzyme A carboxylase (ACC) inhibitor (IC50:6 nM) with antimicrobial activity, strongly inhibiting Gram-positive bacteria but weakly inhibiting Gram-negative bacteria.

[Tyr8] Bradykinin is a B2 kinin receptor agonist. [Tyr8] Bradykinin also stimulates ERK1/2 phosphorylation. [Tyr8] Bradykinin can be used as an internal standard.